ENLV News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

EN

Mkt Cap

$4.5M

Volume

449.70K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

RAIN Highlights $200M Ecosystem Commitment, $100M Liquidity Expansion, and World Cup Growth Strategy Ahead of Version 2 LaunchRAIN, an Arbitrum-based prediction market protocol, announced $200 million in ecosystem commitments through a partnership with Enlivex and $100 million in liquidity expansion ($50M USDT, $50M RAIN). The protocol is preparing for Version 2 launch featuring permissionless market creation, AMMs, on-chain order books, and AI-assisted market resolution, with plans for major expansion around the FIFA World Cup.GlobeNewswire Inc. · Jun 5, 2026

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee OsteoarthritisEnlivex Therapeutics reported positive Phase I/II trial results for Allocetra, showing significant pain reduction and functional improvement in knee osteoarthritis patients, with a favorable safety profile.GlobeNewswire Inc. · Aug 18, 2025

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with OsteoarthritisEnlivex Therapeutics received a notice of allowance for a Japanese patent application covering the use of its Allocetra™ product in treating osteoarthritis, a common and debilitating condition with limited treatment options.GlobeNewswire Inc. · Oct 30, 2024

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee OsteoarthritisKey HighlightsGlobeNewswire Inc. · Jun 17, 2024

Enlivex Therapeutics Closes up to $15 Million Registered Direct OfferingNes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares (or ordinary share equivalents in lieu thereof) and clinical milestone-linked warrants, composed of Series A warrants to purchase up to 3,571,429 ordinary shares and Series B warrants to purchase up to 3,571,429 ordinary shares, at a purchase price of $1.40 per ordinary share (or ordinary share equivalents in lieu thereof) and associated warrants, for aggregate gross proceeds of approximately $5.0 million.GlobeNewswire Inc. · May 29, 2024

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering Nes-Ziona, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale in a registered direct offering of an aggregate of 3,571,429 ordinary shares (or ordinary share equivalents in lieu thereof) and clinical milestone-linked warrants, composed of Series A warrants to purchase up to 3,571,429 ordinary shares and Series B warrants to purchase up to 3,571,429 ordinary shares, at a purchase price of $1.40 per ordinary share (or ordinary share equivalents in lieu thereof) and associated warrants.GlobeNewswire Inc. · May 28, 2024

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisNes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency (DKMA) authorized the expansion into Denmark of the Company’s multi-country, randomized, controlled Phase I/II trial evaluating AllocetraTM in up to 160 patients with moderate to severe knee osteoarthritis. As previously announced, the Company received its first regulatory approval for this trial from the Israeli Ministry of Health (IMOH) in January.GlobeNewswire Inc. · Apr 16, 2024

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's WhyEnlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.Zacks Investment Research · Apr 15, 2024

Tesla To $180? Here Are 10 Top Analyst Forecasts For FridayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup cut the price target for Starbucks Corporation (NASDAQ: SBUX) from $102 to $95. Citigroup analyst Jon Tower maintained a Neutral rating. Starbucks shares fell 0.1% to close at $85.90 on Thursday. See how other analysts view this stock. Citigroup slashed the price target for Tesla, Inc. (NASDAQ: TSLA) from $196 to $180. Citigroup analyst Itay Michaeli maintained a Neutral rating. Tesla shares gained 1.7% to close at $174.60 on Thursday. See how other analysts view this stock. Needham cut CarMax, Inc. (NYSE: KMX) price target from $99 to $91. Needham analyst Chris Pierce maintained a Buy rating. CarMax shares fell 9.2% to close at $71.98 on Thursday. See how other analysts view this stock. Mizuho cut the price target for Phillips 66 (NYSE: Full story available on Benzinga.comBenzinga · Apr 12, 2024

Nasdaq Jumps 250 Points; Crude Oil Down 1%U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83. The S&P 500 also rose, gaining, 0.83% to 5,203.26. Check This Out: How To Earn $500 A Month From Citigroup Stock Ahead Of Q1 Earnings Report Leading and Lagging Sectors Information technology shares rose by 2.2% on Thursday. In trading on Thursday, energy shares fell by 0.3%. Top Headline Constellation Brands Inc (NYSE: STZ) reported better-than-expected fourth-quarter earnings. Constellation Brands reported fourth-quarter FY24 sales growth of 7.1% year-on-year to $2.14 billion, beating the analyst consensus estimate of $2.10 billion. Comparable EPS, excluding Canopy EIE, was $2.30. Comparable EPS of $2.26 beat the consensus estimate of $2.09. Equities Trading UP Rallybio Corporation (NASDAQ: RLYB) shares shot up 87% to $3.0419 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Shares of Eliem ...Benzinga · Apr 11, 2024

EN

ENLVEnlivex Ltd. Ordinary Shares

ENLV

Pay with—

Available Balance0.00

Your PositionYou don't own any ENLV yet.

Related Tickers

Earnings